TORONTO, Oct.  07, 2022  (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy Hewitt has resigned as General Counsel & Corporate Secretary, effective October 7, 2022.
Reunion Neuroscience Inc. Announces Executive Changes
Reunion Neuroscience Inc. Announces Executive Changes --  Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy Hewitt has resigned as General Counsel & Corporate Secretary, effective October 7, 2022.